37.0% growth: At WORLD OF MEDICINE, investments in research and development are paying off
Berlin (euro adhoc) -
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
balance/9-month report
Listed medical device manufacturer WORLD OF MEDICINE achieved a 37.0% growth in sales in the 3rd quarter 2007; cumulatively over nine months, the Group achieved a sales increase of 16.4% to TE25,142. "In the current fiscal year, we have brought a number of innovations to market-ready status," says Peter P. Wiest, CEO of WORLD OF MEDICINE. "It is clear that past investments in research and development are now paying off." The pre-tax sales yield after nine months equaled 15.6% (same period last year: 5.1%). In addition, WORLD OF MEDICINE attained proceeds from the sale of its former subsidiary, IB Laser AG, in the amount of E1.1 million (before taxes).
| |9M/2007 |9M/2006 Change | |Sales |25,142 TE |21,596 TE |+ 16.4% | |EBT |3,927 TE |1,112 TE |+ 2,815TE | |Pre-tax sales yield|15.6 % |5.1 % |> 100% | |Earnings per share |0.54 E |0.07 E |> 100% |
"We are concentrating on the marketing of our new products, on further investments in our core business, and on the area of optical diagnostics with a focus on oncology, which promises to generate attractive growth opportunities in the medium term," states Peter P. Wiest. "For the medium to long term, we are examining the potential synergies and business opportunities that result from the partnership with ATON GmbH." As previously disclosed, WORLD OF MEDICINE is raising its targets for the year 2007, based on the positive business development and the high volume of orders booked. The Management Board
is now projecting a sales increase of at least 10.0% (prior: 4-5%) to more than E34.0 million, and a pre-tax sales yield of at least 13.0% (prior: 10.0%).
WORLD OF MEDICINE and its technologies are paving the way in Minimally Invasive Surgery - or MIS for short. This approach includes safe and gentle surgical procedures conducted not through major incisions, but through keyhole or puncture incisions. The Company is the global market leader in a niche of this future market.
A telephone conference on the quarterly figures is scheduled today at 10:00 a.m. CET for analysts, investors and press representatives. To participate, please contact WORLD OF MEDICINE directly.
end of announcement euro adhoc 07.11.2007 08:00:00
Further inquiry note:
Stefanie Gehrke
Tel.: +49 (0)30 399 81 566
E-Mail: stefanie.gehrke@womcorp.com
Branche: Pharmaceuticals
ISIN: DE0006637390
WKN: 663739
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade